Population Pharmacokinetics of Nevirapine in Thai HIV-Infected Patients

Sungkanuparph S. , Techasathit W. , Utaipiboon C. Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomedicine. 2010; 4: 515–528.

Anekthananon T. , Ratanasuwan W. , Techasathit W. , Sonjai A. , Suwanagool S. Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. J Med Assoc Thai 2004; 87: 760–767.

Manosuthi W. , Sungkanuparph S. , Vibhagool A. , Rattanasiri S. , Thakkinstian A. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naive patients with advanced HIV infection. HIV Med 2004; 5: 105–109.

Chasombat S. , Lertpiriyasuwat C. , Thanprasertsuk S. , Suebsaeng L. , Lo Y.R. The National Access to Antiretroviral Program for PHA (NAPHA) in Thailand. Southeast Asian J Trop Med Public Health 2006; 37: 704–715.

Tin E.E. , Bowonwatanuwong C. , Desakorn V. , Wilairatana P. , Krudsood S. , Pitisuttithum P. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naive adult HIV patients. Southeast Asian J Trop Med Public Health 2005; 36: 362–369.

Kappelhoff B.S. , Crommentuyn K.M. , de Maat M.M. , Mulder J.W. , Huitema A.D. , Beijnen J.H. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet 2004; 43: 845–853.

Cheeseman S.H. , Hattox S.E. , McLaughlin M.M. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother 1993; 37: 178–182.

Riska P. , Lamson M. , MacGregor T. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 1999; 27: 895–901.

Murphy R.L. , Montaner J. Drug evaluations anti-infectives: nevirapine: a review of its development, pharmacological profile and potential for clinical use. Expert Opin Investig Drugs 1996; 5: 1183–1199.

Kappelhoff B.S. , van Leth F. , MacGregor T.R. , Lange J. , Beijnen J.H. , Huitema A.D. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005; 10: 145–155.

Elsherbiny D. , Cohen K. , Jansson B. , Smith P. , McIlleron H. , Simonsson U.S. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. Eur J Clin Pharmacol 2009; 65: 71–80.

Moltó J. , Valle M. , Miranda C. Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach. J Antimicrob Chemother 2008; 62: 784–792.

de Maat M.M. , Huitema A.D. , Mulder J.W. , Meenhorst P.L. , van Gorp E.C. , Beijnen J.H. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol 2002; 54: 378–385.

de Maat M.M. , Huitema A.D. , Mulder J.W. Drug interaction of fluvoxamine and fluoxetine with nevirapine in HIV-1-infected individuals. Clin Drug Investig 2003; 23: 629–637.

Schipani A. , Wyen C. , Mahungu T. Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. J Antimicrob Chemother 2011; 66: 1332–1339.

Dailly E. , Raff F. , Perre P. , Martin J. , Deslandes G. , Jolliet P. Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach. HIV Med 2009; 10: 586–589.

Chou M. , Bertrand J. , Segeral O. Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Antimicrob Agents Chemother 2010; 54: 4432–4439.

Sheiner L. , Grasela T. An introduction to mixed effect modeling: concepts, definitions, and justification. J Pharmacokinet Pharmacodyn 1991; 19: 11S–24S.

de Vries-Sluijs T.E. , Dieleman J.P. , Arts D. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 2003; 42: 599–605.

Havlir D. , Cheeseman S.H. , McLaughlin M. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171: 537–545.

Veldkamp A.I. , Weverling G.J. , Lange J.M. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001; 15: 1089–1095.

Leth F.V. , Kappelhoff B.S. , Johnson D. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res Hum Retroviruses 2006; 22: 232–239.

Kappelhoff B.S. , Huitema A.D. , van Leth F. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. HIV Clin Trials 2005; 6: 254–261.

Manosuthi W. , Sungkanuparph S. , Thakkinstian A. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis 2006; 43: 253–255.

Manosuthi W. , Athichathanabadi C. , Uttayamakul S. , Phoorisri T. , Sungkanuparph S. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. BMC Infect Dis 2007; 7: 14.

Avihingsanon A. , Manosuthi W. , Kantipong P. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antivir Ther 2008; 13: 529–536.

Hollanders R.M. , van Ewijk-Beneken Kolmer E.W. , Burger D.M. , Wuis E.W. , Koopmans P.P. , Hekster Y.A. Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2000; 744: 65–71.

Droste J.A. , Aarnoutse R.E. , Koopmans P.P. , Hekster Y.A. , Burger D.M. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr 2003; 32: 287–291.

Jonsson E.N. , Karlsson M.O. Xpose–an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51–64.

Holford N.H. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30: 329–332.

Ette E.I. , Williams P.J. , Kim Y.H. , Lane J.R. , Liu M-J , Capparelli E V. Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol 2003; 43: 610–623.

Sheiner L.B. , Beal S.L. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503–512.

Bland J.M. , Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307–310.

Svensson E. , van der Walt J.S. , Barnes K.I. Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. Br J Clin Pharmacol 2012; 74: 465–476.

Svärd J. , Spiers J.P. , Mulcahy F. , Hennessy M. Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans. J Acquir Immune Defic Syndr 2010; 55: 536–549.

Navaratnarajah P. , Steele B.L. , Redinbo M.R. , Thompson N.L. Rifampicin-independent interactions between the pregnane X receptor ligand binding domain and peptide fragments of coactivator and corepressor proteins. Biochemistry 2012; 51: 19–31.

Moreira R.P. , Jorge A.A. , Mendonca B.B. , Bachega T.A. Frequency of genetic polymorphisms of PXR gene in the Brazilian population. Clinics (Sao Paulo) 2011; 66: 1041–1044.

King C.R. , Xiao M. , Yu J. Identification of NR1I2 genetic variation using resequencing. Eur J Clin Pharmacol 2007; 63: 547–554.

Hustert E. , Zibat A. , Presecan-Siedel E. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 2001; 29: 1454–1459.

Wang X.D. , Deng X.Y. , Chen J. Single nucleotide polymorphisms of the pregnane x receptor gene in Han Chinese and a comparison with other ethnic populations. Pharmacology 2008; 81: 350–354.

Lamba J. , Lamba V. , Strom S. , Venkataramanan R. , Schuetz E. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 2008; 36: 169–181.

Zhang B. , Xie W. , Krasowski M.D. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 2008; 9: 1695–1709.

Piedade R. , Schaeffeler E. , Winter S. PXR variants and artemisinin use in Vietnamese subjects: frequency distribution and impact on the interindividual variability of CYP3A induction by artemisinin. Antimicrob Agents Chemother 2012; 56: 2153–2157.